BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 28646959)

  • 1. Is chickenpox so bad, what do we know about immunity to varicella zoster virus, and what does it tell us about the future?
    Gershon AA
    J Infect; 2017 Jun; 74 Suppl 1(Suppl 1):S27-S33. PubMed ID: 28646959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varicella Virus Vaccination in the United States.
    Shaw J; Gershon AA
    Viral Immunol; 2018 Mar; 31(2):96-103. PubMed ID: 29173081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Varicella and herpes zoster vaccine development: lessons learned.
    Warren-Gash C; Forbes H; Breuer J
    Expert Rev Vaccines; 2017 Dec; 16(12):1191-1201. PubMed ID: 29047317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
    Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P
    Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster.
    Gershon AA; Gershon MD; Shapiro ED
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S387-S397. PubMed ID: 34590140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vaccines against varicella-zoster virus (VZV)].
    Salleras L; Salleras M; Soldevila N; Prat A; Garrido P; Domínguez Á
    Enferm Infecc Microbiol Clin; 2015; 33(6):411-23. PubMed ID: 26096575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current status of live attenuated varicella vaccine.
    Gershon AA
    Arch Virol Suppl; 2001; (17):1-6. PubMed ID: 11339539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of vaccination on the epidemiology of varicella zoster virus.
    Edmunds WJ; Brisson M
    J Infect; 2002 May; 44(4):211-9. PubMed ID: 12099726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying optimal vaccination scenarios to reduce varicella zoster virus transmission and reactivation.
    Bakker KM; Eisenberg MC; Woods RJ; Martinez ME
    BMC Med; 2022 Oct; 20(1):387. PubMed ID: 36209074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Varicella and herpes zoster vaccines: WHO position paper, June 2014.
    Wkly Epidemiol Rec; 2014 Jun; 89(25):265-87. PubMed ID: 24983077
    [No Abstract]   [Full Text] [Related]  

  • 11. Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination.
    Horn J; Karch A; Damm O; Kretzschmar ME; Siedler A; Ultsch B; Weidemann F; Wichmann O; Hengel H; Greiner W; Mikolajczyk RT
    Hum Vaccin Immunother; 2016 Jul; 12(7):1766-76. PubMed ID: 26835890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.
    Wolff E; Widgren K; Scalia Tomba G; Roth A; Lep T; Andersson S
    PLoS One; 2021; 16(5):e0251644. PubMed ID: 33984060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies.
    Freer G; Pistello M
    New Microbiol; 2018 Apr; 41(2):95-105. PubMed ID: 29498740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspective on live varicella vaccine.
    Gershon AA; Katz SL
    J Infect Dis; 2008 Mar; 197 Suppl 2():S242-5. PubMed ID: 18419404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Live attenuated varicella vaccine.
    Arvin AM; Gershon AA
    Annu Rev Microbiol; 1996; 50():59-100. PubMed ID: 8905076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular studies of the Oka varicella vaccine.
    Quinlivan M; Breuer J; Schmid DS
    Expert Rev Vaccines; 2011 Sep; 10(9):1321-36. PubMed ID: 21919621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing varicella-zoster disease.
    Hambleton S; Gershon AA
    Clin Microbiol Rev; 2005 Jan; 18(1):70-80. PubMed ID: 15653819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs for varicella-zoster virus infections.
    Andrei G; Snoeck R
    Expert Opin Emerg Drugs; 2011 Sep; 16(3):507-35. PubMed ID: 21699441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased varicella and increased herpes zoster incidence at a sentinel medical deputising service in a setting of increasing varicella vaccine coverage in Victoria, Australia, 1998 to 2012.
    Kelly HA; Grant KA; Gidding H; Carville KS
    Euro Surveill; 2014 Oct; 19(41):. PubMed ID: 25345520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis and current approaches to control of varicella-zoster virus infections.
    Gershon AA; Gershon MD
    Clin Microbiol Rev; 2013 Oct; 26(4):728-43. PubMed ID: 24092852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.